Health Care Professionals

Click here to view a Compendium of Clinical Cases and Clinical Decision Making titled "A Breakthrough Medical Approach in the Management of Patients with Diabetic Neuropathy."

This information was published in the December 2005 issue of Vascular Disease Management and Podiatry Today as a supplement.

Vascular Disease Management and Podiatry Today are published by HMP Communications.

---

Metanx^® Information ¹

• Late breaking clinical evidence
  IMT and Folate Study Abstract.
• Prescribing Information
  Filesize: 23kb
• Medical References
  Published studies regarding the relationship between elevated homocysteine levels and increased cardiovascular risk.

Metanx^® features L-Methylfolate (Metafolin^®), the active form of Folate.

• Up to 50% of patients are unable to fully convert folic acid into the active form of folate, L-methylfolate.
• There is no conversion required with L-methylfolate.

Metanx^® has a unique formulation providing your patients the active forms of folate, vitamin B₆ and vitamin B₁₂.

Each Metanx^® tablet contains:

L-methylfolate (Metafolin^®)

2.8 mg

Pyridoxal 5'-phosphate

25 mg

Methylcobalamin

2 mg

---

* Malinow MR. etal, Homocysteine, Diet and Cardiovascular Diseases. A Statement For Healthcare Professionals From The Nutritiion Committee, American Heart Association. Circulation 1999;99:178-182.

¹ Requires Adobe Acrobat reader to view.